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Summary Two liposomal formulations of mitoxantrone (MTO) were compared with the aqueous solution (free MTO) in terms of their
pharmacokinetic behaviour in ICR mice and cytotoxic activity in a nude mouse xenograft model. The three different formulations of MTO [free
MTO, phosphatidic acid (PA)-MTO liposomes, pH-MTO liposomes] were administered intravenously (three mice per formulation and time
point) at a dose of 4.7 [imol kg-' for free MTO, 6.1 imol kg-' for PA-MTO and 4.5 Imol kg-' for pH-MTO. The concentrations of MTO were
determined using high-performance liquid chromatography (HPLC) in blood, liver, heart, spleen and kidneys of the mice. Additionally, the
toxicity and anti-tumour activity of MTO was evaluated in a xenograft model using a human LXFL 529/6 large-cell lung carcinoma. The dose
administered was 90% of the maximum tolerated dose (MTD) ofthe corresponding formulation (8.1 Amol kg-' forfree MTO, 12.1 iimol kg-' for
PA-MTO and pH-MTO). The pharmacokinetic behaviour of PA-MTO in blood was faster than that of free MTO, but the cytotoxic effect was
improved. In contrast, pH-MTO showed a tenfold increased area under the curve (AUC) in blood compared with free MTO, without
improvement of the cytotoxic effect. This discrepancy between the pharmacokinetic and cytotoxic results could be explained by the fact that
MTO in pH-MTO liposomes remains mainly in the vascular space, whereas MTO in PA-MTO liposomes is rapidly distributed into deep
compartments, even more so than free MTO.
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Mitoxantrone (MTO, Novantrone) or 1,4-dihydroxy-5,8-bis {{2-
[(2-hydroxyethyl)-amino]ethyl}amino}-9,10-anthracenedione dihy-
drochloride is active against lymphomas, breast cancer, acute
leukaemias and other malignancies (Shenkenberg and von Hoff,
1986, Faulds et al, 1991). The dose-limiting toxicity of M1O is
myelosuppression, but cardiotoxicity may also occur. The risk of
cardiomyopathy increases as the total cumulative dose of MiX
increases, but it is considerably lower than that with the structurally
related anthracyclines. An overall incidence of MTO-associated
cardiac effect of 3% in adults and 6% in children has been reported
(DuKart et al, 1985); the estimated worst-case incidence ofconges-
tive heart failure being 1.3% compared with 2.2% with doxorubicin.
Forthe treatment ofsolidtumours,MTO isgenerally administered as
asingle short-time infusionevery 3 weeks atadoseof 12-14mg in-2.
Although MTO features structural similarities to doxorubicin
and other DNA-intercalating agents, significant differences in the
mechanism ofaction were found. At least three mechanisms were
described: stabilization of the topoisomerase-DNA cleavable
complex, which prevents rejoining of strand breaks; aggregation
and compaction of DNA via electrostatic cross-linking interac-
tions; and oxidative activation of MTO with free radical genera-
tion inducing non-protein-associated strand breaks (Alberts et al,
1985a; Blanz et al, 1991; Faulds et al, 1991).
To improve the anti-tumour activity and to reduce toxicity of
various other anthracyclines, liposomal formulations were
prepared. With doxorubicin (Gabizon et al, 1992; Gabizon, 1993),
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daunorubicin (Forssen et al, 1992) and epirubicin (Mayhew et al,
1992), it was shown that because of changed pharmacokinetic
behaviour (Gabizon et al, 1993) and changed tissue distribution
(Forssen et al, 1992) the overall therapeutic index of these anti-
tumour drugs could be improved.
Different techniques have been developed to incorporate hydro-
philic drugs into liposomes. The first method uses a proton
gradient to actively load the liposomes with the drug (Mayer et al,
1986). By lowering the pH in the inner compartment of the lipo-
somes, basic drugs diffuse along the pH gradient into the lipo-
somes, where they interact with the corresponding counterions
(e.g. sulphate, citrate) (Mayer et al, 1985; Madden et al, 1991;
Gabizon, 1992). The disadvantage of this 'remote loading' tech-
nique is the rather low stability of the drug and proton gradient.
Another possibility to associate hydrophilic basic drugs with lipo-
somes is to complex them with negatively charged components of
the liposome membrane (Amselem et al, 1990; Schwendener et al,
1991). A third technique involves the modification ofhydrophilic
drugs into lipophilic derivatives (prodrugs). These molecules are
incorporated as lipophilic components into the liposomal
membrane (Rahman et al, 1986; Rubas et al, 1986).
Two different liposomal formulations were developed with
MTO: the first formulation containing phosphatidic acid (PA) to
which MTO was complexed (PA-MTO liposomes) (Schwendener
et al, 1991) and the second using the 'remote loading' technique
(pH-MTO liposomes) (Schwendener et al, 1994). In addition to the
different loading techniques of the liposomes with MTO, the
pH-MTO liposomes contained poly (ethylene) glycol (PEG)-modi-
fied dipalmitoyl phosphatidylethanolamine (PEG(2000)-DPPE) to
provide them with long circulating properties (Allen, 1989; Lasic et
al, 1991; Gabizon etal, 1993). In orderto compare thepharmacoki-
netic parameters of these two liposomal formulations with the
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aqueous solution that is currently on the market, the concentrations
of MTO were measured using high-performance liquid chro-
matography (HPLC) in blood, liver, heart, spleen and kidneys of
mice after intravenous administration of the three formulations.
Our goal was to compare the pharmacokinetic properties of MTO
in mice after the application of the different pharmaceutical
formulations to study the differences in the organ distribution.
Additionally, the toxicity and anti-tumour activity of MTO after
administration of the different formulations were evaluated in a
human xenograft model.
MATERIALS AND METHODS
Preparation of MTO formulations
Aqueous MTO solution (free MTO)
MTOdihydrochloride [Cyanamid(Schweiz), Lederle Arzneimittel,
Adliswil, Switzerland] was dissolved in 0.9% saline. The final
concentration was 1261 [imol 1-1.
PA-MTO liposomes (PA-MTO)
Small unilamellar liposomes were prepared by detergent dialysis
as describedby Schwendener et al (1991). MTO was complexed to
PA in the aqueous micellar solution before liposome formation.
The acid phosphohydroxy groups of PA associate with the pair of
basic secondary amino groups on the side chains ofMTO. Because
ofits amphiphilic properties, the MTO-PA complex is statistically
distributed over both membranes of the liposome. The composi-
tion of the liposomes was as follows: soy phosphatidylcholine
(SPC)/cholesterol/ phosphatidic acid (PA)/MTO/a-tocopherol =
1: 0.21 : 0.056: 0.028 : 0.001 (mol). The liposomes were filtered
through 0.45-[tm sterile filters (Nalge, Rochester, NY, USA) and
stored at4°C. The final concentration ofMTO was 766 [tmol 1-1.
pH-MTO liposomes (pH-MTO)
MTO was loaded into the aqueous inner compartment ofpreformed
liposomes using a gradient of 10 pH units (Schwendener et al,
1994). Liposomes ofthe composition SPC/cholesteroll PEG(2000)-
DPPE = 1: 0.2 : 0.1 (mol) were prepared at pH 2 in ammonium
sulphate (0.1 M) by extrusion through 0.1-[tm Nucleopore filters.
The pH of the external medium was then raised by elution of the
liposomes on a Sephadex G75 column which was pre-equilibrated
at pH 12. The liposomes were then incubated with 0.2 JLM MTO
dihydrochloride per 1 [tM SPC. Unencapsulated MTO was removed
by binding to Dowex 50Wx2 (Fluka, Buchs, Switzerland) resin,
followedbyreadjustment oftheliposomes topH 7.4 withphosphate
buffer by another column chromatography step. Thioglycerol (1 tl
per pmol of MTO) was added as antioxidant, and the liposomes
were filtrated with 0.2-jm filters (Acrodisc, Gelman Sciences,
Ann Arbor, MI, USA). The final concentration of MTO was
1306 itmol 1l.
Pharmacokinetic analysis in mice
Animals
The experiments were performed using female ICR mice (body
weight 20-30 g). The animals were housed in air-conditioned
rooms on a 12 h/12 h light/dark schedule. Tap water and a
commercial,pelleted maintenance diet were fed ad libitum. Either
100 pl of the free MTO and pH-MTO formulations or 200 [tl of
the PA-MTO liposomes were injected intravenously into the tail
vein, corresponding to a dose of 4.7 limol kg-' for free MTO, 6.1
ptmol kg-' for PA-MTO and 4.5 [tmol kg-' forpH-MTO. For each
pharmaceutical formulation and each time point of measurement,
three mice were used. Five and thirty min, 1,2,3 and 24 h after the
injection of MTO, the mice were sacrificed by heart puncture
underetheranaesthesia, andblood, liver, spleen, heart andkidneys
were removed and immediately frozen. To prevent oxidative
degradation of mitoxantrone, 20 pt1 of a solution containing
ascorbic acid (100 mg ml-' in 0.1 M citrate buffer pH 3.0) was
added to each tube before collecting the blood samples.
Samplepreparation and druganalysis
The methods for sample preparation and drug analysis ofMTO by
HPLC have been reported previously (Rentsch et al, 1996). All
glassware was silanized using Sylon CT (5% dimethyldichlorosi-
lane in toluene) from Supelco (Bellefonte, PA, USA). Briefly,
homogenization of tissues (liver, spleen, heart, kidney) was
performed with a potter on ice in a solution of20% ascorbic acid in
0.1 M citrate buffer (pH 3.0). To 50 mg oftissue, 1 ml ofbuffer was
added. An aliquot of 1 ml of a solution containing hexane
sulphonic acid (0.01 mg ml-'), ascorbic acid (0.5 mg ml-') and
ametantrone (0.08 mg ml-', AMT; Drug Synthesis and Chemistry
Branch, Developmental Therapeutics Program, Division ofCancer
Treatment, National Cancer Institute, Rockville, MD, USA), as
internal standard, was added to 1 ml oftissue homogenate or whole
blood. After vortexing for 30 s, 1 ml of0.1 M borate buffer (pH 9.5)
and 300 pl of a 1 N sodium hydroxide solution were added and
vortexed again for 30 s. Extraction was performed with 5 ml of
dichloromethane on a horizontal shaker (Infors HT, Infors,
Bottmingen, Switzerland) during 60 min at 150 r.p.m. After
centrifugation for 15 min at 2800g,the organic layer was separated
and dried by evaporation (Rotavapor, Buchi, Flawil, Switzerland),
and the residue was dissolved in 150 ptl ofmobile phase.
Samples (92 p.l) were injected into a 250 x 4-mm Nucleosil
C column (Macherey Nagel, Oensingen, Switzerland) using
an autosampler (9100, Varian, Sunnyvale, CA, USA). The
HPLC column was eluted with acetonitrile (33%) and 0.16 M
ammonium formate buffer (67%) pH 2.7 at a flow of 1.0 ml min-'.
Hexane sulphonic acid was added at a concentration of 0.25 M.
MTO was quantitated by UV detection using a 9050 UV-VIS
Detector (Varian, Sunnyvale, CA, USA) set at 658 nm. The linear
range was 4-400 nmol 1-1 whole blood and 4-1400 nmol 1-1 tissue
homogenate, and the coefficients of variation within-day and
between-days were below 4.5% for whole blood and below 10%
for tissue homogenates (Rentsch et al, 1996).
Pharmacokinetic analysis
All animals were injected i.v. with the same amount ofMTO ofthe
respective formulation, irrespective oftheir body weight. In order
to compare directly the pharmacokinetic parameters of the
different pharmaceutical formulations, all measured concentra-
tions of MTO were corrected to a dose of4.5 ,umol per kg ofbody
weight and the mean body weight of27.3 g (standard deviation 2.5
g, n = 54). The concentrations of MTO in the different tissues
analysed were corrected for the amount of MTO in the residual
tissue blood (Allen, 1989; Khor and Mayersohn, 1991). The area
under the curve ofdrug concentration as a function oftime (AUC)
and the area under the moment curve (AUMC) were determined
with the trapezoidal rule over a period of 24 h for all organs
studied. In addition, AUC and AUMC were also determined for
infinite time in the case of whole blood.
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Calculations were made as follows:
* Mean residence time (MRT):
AUMC (00)
AUC (oo)
* Total clearance(Cl,0,):
Clt,t = Dose
AUC (00)
* Volume ofthe central compartment (V,):
VI = Dose
c(O)
* Steady-state volume ofdistribution (VS,):
VSs =MRT x Cl,o,
The initial concentration [c(0)] was extrapolated from the intra-
venous data.
Toxicity and anti-tumour activity in a human xenograft
model
For in vivo experiments, 6- to 8-week-old female athymic nude
mice of NMRI genetic background were used. The evaluation of
the anti-tumour activity was performed as described earlier
(Schwendener et al, 1991). Briefly, tumour slices ofhuman LXFL
529/6 large-cell lung carcinoma were implanted s.c. into both
flanks ofthe animals. The experiment was started after 3-6 weeks
when the median tumourdiameterhadreached 6 mm and the mean
body weight ofthe mice was 28.5 g (standard deviation 3.1 g, n =
12). At day0,the mice were randomized into treatmentgroups and
control groups each consisting of four mice, which resulted in
eight tumours to be evaluated in each group. All compounds were
injected as a single dose on day 1 at 90% ofthe maximal tolerated
dose (MTD), which was 8.1 iimol kg-' for free MTO and 12.1
itmol kg-' for PA-MTO and pH-MTO. The control group
remained untreated. Tumour growth was recorded weekly by
measurement of two perpendicular diameters (a,b), with (a x b2)
representing the tumour size. The relative tumour volume (RTV)
was calculated for each single tumour by dividing the tumour size
on the day of evaluation by that on the day of randomization.
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Figure 1 The concentration of MTO (tmol 1-1) (mean and standard deviation)
in whole blood as a function of time (min) of free MTO (*), PA-MTO (M) and
pH-MTO (0). The vertical bars represent the standard deviations of the
mean (n = 3). The administered doses were 4.7 imol kg-' MTO with free
MTO, 6.1 [tmol kg-' with PA-MTO and 4.5 imol kg-' with pH-MTO
Median RTV values were used for further evaluation. The anti-
tumour effect was evaluated following maximal tumour regres-
sion. To estimate toxicity of the different pharmaceutical
formulations, the body weight of the mice was monitored during
the whole observation period. The relativebody weight was calcu-
lated by dividing the body weight on the day ofevaluation by that
on the day of randomization. The death of the animals character-
ized the end ofthe observation period.
RESULTS
Pharmacokinetic analysis in mice
Whole blood
Mice were injected (i.v. bolus) with each ofthe three MTO formu-
lations described in Materials and methods. The corresponding
concentration-time profiles are shown in Figure 1. Over the whole
time of observation, concentrations of MTO were tenfold higher
with pH-MTO than with free MTO and PA-MTO. The pharmaco-
kinetic parameters, summarized in Table 1, were calculated from
these data with a non-compartmental model. As expected, the area
under the curve was highest for pH-MTO, ninefold higher than
that for free MTO and 22-fold higher than that for PA-MTO.
Accordingly, the mean residence time for pH-MTO was threefold
lower than that for free MTO and twofold lower than that for
PA-MTO. The total clearance in pH-MTO was ninefold lower
than that for free MTO and 20-fold lower than that for PA-MTO.
The volume of the central compartment was smallest for
pH-MTO, namely sevenfold lower than that for free MTO, and
17-fold lower than that for PA-MTO. Finally, the steady-state
volume of distribution for pH-MTO was 29-fold lower than that
for free MTO and 37-fold lower than that for PA-MTO.
Tissue distribution
For all three formulations, the amounts of MTO in whole blood,
liver, spleen, heart and kidney were determined as described. Time
profiles describing the percentage of the drug in each organ are
represented in Figure 2A-C. Comparing identical time points, the
amount of MTO being found in a single tissue was consistently
higher than that detected in whole blood, with the exception ofthe
5- and 30-min time points for pH-MTO (Figure 2C). With all
formulations, the highest amount of MTO was found in the
kidneys. With free MTO and PA-MTO, the maximal concentra-
tions in liver and kidneys were reached within 5 min and in spleen
Table 1 Pharmacokinetic data of whole blood
Parameter Free MTO (mean) PA-MTO (mean) pH-MTO (mean)
c(O) ([Imol 1-') 9.73 3.58 64.6
AUC(oo) (iimol min 1-')
(% extrapolated) 408 (28.1) 163 (13.6) 3516 (5.6)
MRT (min) 1087 554 325
CIt,t (ml min-') 0.30 0.76 0.035
V, (ml) 13.0 33.1 1.99
V, (ml) 328 419 11.4
For each formulation and time point, three ICR mice were injected intravenously
with 4.7gmol kg-' free MTO, 6.1 imol kg-' PA-MTO and 4.5 imol kg-'
pH-MTO. For pharmacokinetic calculations, the concentrations of MTO were
corrected to a dose of4.5ilmol kg-' and a mean bodyweight of 27.3g.
British Journal ofCancer(1997) 75(7), 986-992 0CancerResearchCampaign 1997Pharmacokinetics andcytotoxicity ofmitoxantrone 989
0 200 400 600 800 1000 1200 1400
Time (min)
S
K
,-
0 200 400 600 800 1000
Time (min)
0 200 400 600 800
Time (min)
1200 1400
1000 1200 1400
Figure 2 Comparison of the time courses of MTO (% of dose) in heart (0),
spleen (A), whole blood (V), liver (*), kidneys (U) and the total recovery (O)
after the application of (A) 4.7 imol kg-' MTO as free MTO, (B) 6.1 imol kg-'
MTO as PA-MTO and (C) 4.5 imol kg-' MTO as pH-MTO. The data points
represent the percentual values of the means of the amount of MTO in the
whole organs determined by HPLC
and heart within 30 min. With pH-MTO, the maximal concentra-
tions in liver, heart and kidneys were reached within 30 min and in
spleen within 60 min. For quantitative comparisons, the following
parameters were determined: amount of MTO (percent of dose)
in the different tissues 5 min after injection, the AUC (24 h),
determined per gram organ weight over a period of 24 h and the
relative AUC (24 h), i.e. the proportional AUC of a single organ of
the total AUC with correction for organ weight (Table 2). The total
recovery of MTO S min after injection was as follows: for
pH-MTO, 107% of the injected dose was recovered with more
than 85% in blood; for pH-MTO, a recovery of only 25% of the
injected dose was found in the organs that were studied, most ofit
Table 2 Pharmacokinetic data in whole blood and tissues (non-
compartmental modelling)a
Parameters Free MTO (mean) PA-MTO (mean) pH-MTO (mean)
AmountofMTO 5min afterinjection (% ofdosep
Blood 11.7 4.2 88.4
Liver 25.0 14.0 10.4
Spleen 1.1 0.3 0.6
Heart 1.6 0.3 0.5
Kidneys 35.6 6.3 7.4
Recovery 75 25 107
AUC (24 h) (,umolmin kg-1)C
Blood 0.32 0.12 3.51
Liver 6.53 5.18 12.7
Spleen 19.4 5.72 24.1
Heart 12.7 4.32 7.20
Kidneys 84.7 29.0 61.5
Relative AUC (% oftotalAUC) (24 h), correctedfororgan weight.d
Blood 1.5 1.5 15.6
Liver 19.8 42.4 33.2
Spleen 4.5 3.7 5.0
Heart 3.7 2.2 1.8
Kidneys 70.5 50.2 44.4
1 100 100 100
aThe dose administered was 4.7[tmol kg-' for free MTO, 6.1 [tmol kg-' for
PA-MTO and 4.5 jAmol kg-' for pH-MTO (three mice per time point and
formulation). bAmount of MTO, expressed as per cent ofdose, found in the
different tissues 5 min after injection of MTO. cArea under the curve (AUC)
determined over a period of 24 h in the different tissues. dRelative AUC in the
different organs, calculated as per cent of the total AUC in the tissues
analysed, which were corrected for organ weight.
in the liver (14%) and less than 5% in the blood; forfree MTO, the
recovery was 75%, with the highest amount in the kidneys (36%),
a considerable amount in the liver (25%) and only 11.7% in the
blood. Forall threeformulations, the amount was low in the spleen
(s 1.2%). For the quantitative comparison of the various organs,
the relative AUC (24 h) withcorrection fororgan weight was used.
Again, for all three preparations the highest values were found in
the kidneys, followedby the liver. In heart and spleen, values were
below 5% in all cases. In whole blood, a value of 16% was found
with pH-MTO compared with < 2% for the other two formula-
tions. Comparison between the formulations showed that the rela-
tive AUC value in the kidneys was about 50% for the liposomal
formulations and 70% for free MTO, whereas in the liver the rela-
tive AUC was higher for the liposomal preparations (42% and
33%) compared with free MTO (20%).
Toxicity and anti-tumour activity in a human xenograft
model
Toxicity
During 21 days, the animals of the control group did not change
their body weight, whereas all treated animals had a reduced body
weight after the chemotherapy. The maximum tolerated dose
(MTD) offree MTO in tumour-bearing nude mice was determined
to be 9.0 itmol kg-', given i.v. on day 1. After 21 days, the
mortality was 20% (one out of five mice) and the median loss of
body weight was 8%. For PA-MTO, the MTD was found to be
13.5 jtmol kg-', given i.v. on day 1, resulting in a mortality of0%
(none out of four mice) and a median body weight loss of 9% on
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Figure 3 Median relative tumour volume (a x b')12 (%) of the human
xenograft LXFL 529/6 after chemotherapy on day 1 with different
pharmaceutical formulations: free MTO (*), PA-MTO (U), pH-MTO (0) and
controls (C). The administered doses were 8.1 Rmol kg-' MTO with free
MTO, 12.1 [tmol kg-' MTO with PA-MTO and 12.1 jumol kg-' MTO with
pH-MTO, respectively, corresponding to 90% of the maximum tolerated dose
for the respective formulation
day 21. ForpH-MTO, the corresponding data were 13.5 iimol kg-'
as MTD with a mortality of 25% (one out of four mice) and a
median body weight loss of 3%. The minimal relative body weight
(RBW) was determined on day 49 for free MTO (RBW 79%), on
day 105 for PA-MTO (RBW 67%) and on day 10 for pH-MTO
(RBW 83%). The animals treated with free MTO and PA-MTO
did not recover during the observation period, whereas the animals
treated with pH-MTO recovered after 21 days. Considerable toxi-
city was found for free MTO at 16 jtmol kg-' and at 20 [tmol kg-'
for PA-MTO and pH-MTO.
Efficacy
The anti-tumour activity of the three formulations was tested in a
LXFL 529/6 human xenograft model. The treatment groups
received a single i.v. dose of 8.1 jtmol kg-' MTO with free MTO
and 12.1 iimol kg-' MTO with PA-MTO and pH-MTO. In Figure
3, the relative tumour volume ofthe LXFL 529/6 human xenograft
is shown as a function of time after randomization of the mice.
Tumours in control animals grew progressively, showing a median
tumour-doubling time of 5 days. With all MTO preparations,
partial remissions were achieved (free MTO and pH-MTO within
28 days, PA-MTO within 21 days). The maximal tumour regres-
sion was obtained with PA-MTO with a tumour volume of 11% of
the initial value, followed by pH-MTO with a tumour volume of
18% of the initial value and free MTO with a tumour volume of
40% of the initial value. To obtain some information on the toxi-
city of the three different formulations ofMTO, changes in weight
over time were registered. During 21 days, the control group did
not change its body weight, whereas all treated animals had a
reduced body weight after the chemotherapy.
DISCUSSION
Drugs that are liposome bound have firstly to be released from their
vehicle to distribute to either plasma proteins, blood cells or
different tissues. This complicates the comparison ofthe pharmaco-
kinetic data in whole blood after the administration of free MTO
and the two liposomal formulations (PA-MTO and pH-MTO).
Because ofanalyticaldifficulties,it was notpossible to separate free
MTO from the liposome-associated drug. In earlier studies, using
[251I]tyraminylinulin as liposome marker, 25% of the liposomes
could be recovered in blood 10 min after the administration of
PA-MTO butonly 0.8% ofthe applied MTO (data not shown). Four
hours after the administration of PA-MTO, 25% of the liposomes
and only 0.1% ofMTO were recovered. With pH-MTO, 60% ofthe
liposomes and 25% ofMTO were recovered 10 min after its admin-
istration; after 4 h, 40% of the liposomes and 3% of MTO were
recovered (Schwendener et al, 1994). These results demonstrate that
both the complexation ofMTO to PA and the incorporation ofMTO
using a pH gradient do not generate in vivo a stable liposome
formulation with MTO. Therefore, when interpreting the pharmaco-
kinetic results ofthe three pharmaceutical formulations ofMTO, the
influence ofthe liposome-bound amount of MTO can be neglected,
at least for the later time points after drug application.
As stated in the Materials and Methods section, we corrected all
measured concentrations of MTO to a mean dose of 4.5 [imol kg-'
and a mean body weight of27.3 g for the pharmacokinetic analyses.
The highest blood concentrations over the whole time ofobservation
could be determined after the administration of pH-MTO and,
accordingly, a significantly larger AUC in blood was calculated than
for the other two formulations. Therefore, pH-MTO would be
expected to be the preparation with the best cytotoxic activity; the
results of the human xenograft model shown in Figure 3 suggest
otherwise. The apparent discrepancy can be explained by the phar-
macokinetic behaviour of the three formulations. Interesting infor-
mation was obtained from the comparison ofthe respective volumes
of distribution. For pH-MTO, both the central volume of distribu-
tion (V,) and the steady-state volume ofdistribution (V s) were much
smaller than those for the other two formulations. The VI of
pH-MTO (2 ml) corresponded to the total blood volume of mice,
suggesting that MTO in this pharmaceutical formulation remained
in the central volume immediately after administration. The balance
5 min after the injection of MTO confirmed this result. For
pH-MTO, 88% ofthe administered dose was found in blood 5 min
after injection, the respective value for free MTO was 12% and for
PA-MTO 4%. At steady state conditions, the volume ofdistribution
of pH-MTO (11 ml) was still lower than the volume of total body
water in mice (18 ml). Free MTO and PA-MTO exhibited a much
larger V , indicating that MTO in thesepharmaceuticalformulations
was accumulating in deep compartments. Another pharmacokinetic
parameter which allowed interpretation of the divergent results of
blood AUC and cytotoxicity was the mean residence time (MRT). It
could be demonstrated that although the AUC in blood was much
higher with pH-MTO, the MRT of pH-MTO was threefold
decreased compared with free MTO. After the administration of
pH-MTO, the cytostatic drug was found at high concentrations in
blood, but it was not distributed into the different tissues in high
quantities. Therefore, the cytotoxic effect on the tumour in the
human xenograft model was lowerthan thatobserved forfree MTO.
With PA-MTO, blood levels were about tenfold lower than those
determined for pH-MTO but, because of the better tissue penetra-
tion of MTO, cytotoxicity was superior. These results support the
statement of Liliemark and Peterson (1991) that a higher plasma
concentration does notnecessarily correlate witha morepronounced
cytotoxic effect.
About 18% of the MTO dose administered in its free form is
excreted in the faeces within 5 days and approximately 10% was
recovered in the urine (Alberts et al, 1985a). The fact that MTO is
rapidly released from both liposome formulations after i.v. admin-
istration implies no changes in the excretion pattern with these
pharmaceutical formulations.
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In the tissues analysed, 5 min after the administration, the entire
amount of MTO was recovered in the case of pH-MTO, three-
quarters of the dose were found with free MTO and only one
quarter of the dose with PA-MTO (Table 2). This indicates that
MTO as free MTO and PA-MTO accumulated in other tissues
that were not analysed. In human autopsy tissues, the highest
amounts of MTO were found in thyroid, liver, heart, pancreas and
spleen in patients with various tumours (Stewart et al, 1986).
Alberts et al (1985b) reported in their study on the disposition of
MTO in cancer patients that MTO appeared to distribute into a
deep tissue compartment from which it was slowly released.
Roboz et al (1984) stated in a case report that MTO must be
distributed in the visceral tissues. Batra et al (1986) reported on the
comparative tissue distribution of '4C-labelled MTO following a
single i.v. dose. They demonstrated that MTO accumulates in rats
in lung tissue. In contrast, in human studies only small concentra-
tions of MTO are found in this organ. Other tissues with high
concentrations ofMTO per g of tissue were thyroid and pancreas.
After the administration of pH-MTO, MTO remained mainly in
blood as we demonstrated by the elevated concentration of MTO
in blood over the whole time of observation (Figure 1). The small
differences in the amount of MTO administered did not influence
the distribution ofMTO in the different tissues, as shown by others
(Batra et al, 1986).
Cardiotoxicity is the most important side-effect besides the
dose-limiting haematological toxicity. After administration of
liposomal MTO (either PA-MTO or pH-MTO), the relative AUC
in heart tissue was slightly decreased compared with that deter-
mined for free MTO. Therefore, a reduced risk ofcardiomyopathy
can be expected after the administration ofthe liposomal formula-
tions. The relative AUC in the spleen did not depend on the phar-
maceutical formulation, indicating that no accumulation of MTO
occurred after injection of the liposomal encapsulated drugs. In
contrast, the relative AUC in liver tissue was remarkably increased
with PA-MTO compared with free MTO and only slightly
increased with pH-MTO. To explain this result, the coating of the
liposomes must be considered. Poly(ethylene)glycol-modified
dipalmitoyl phosphatidyl-ethanolamine (PEG(2000)-DPPE), the
liposome coating used in pH-MTO, is able to significantly inhibit
the uptake ofthe liposomes by the Kupffer cells in the liver (Lasic
et al, 1991). In contrast, the PA-MTO liposomes were uncoated
and probably carrying negative surface charges and therefore more
likely to be rapidly taken up by the mononuclear phagocytic
system (MPS).
In conclusion, the pharmacokinetic and cytotoxic behaviour of
MTO in mice was compared after administration ofthree pharma-
ceutical formulations. pH-MTO showed a tenfold increased AUC
in blood compared with free MTO, without improvement of the
cytotoxic effect. PA-MTO exhibited faster blood pharmacoki-
netics than free MTO, but it had an improved cytotoxic effect. This
discrepancy between the pharmacokinetic and cytotoxic results
could be explained by the fact that MTO in pH-MTO liposomes
remained mainly in the vascular space, whereas MTO in PA-MTO
liposomes was rapidly distributed into deep compartments, even
more so than free MTO.
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